Accepts insurance
Listing updated Oct 2, 2026
Dr. Angela Tran, D.O.
Dr. Angela Tran, D.O. · 2373 Central Park Boulevard · Denver, CO 80238
4.8· 136 Google reviews
Listing updated October 2, 2026
Retatrutide outlook for this practice
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- GLP-1 medications named on site
- Medically supervised weight loss
Services & access
| Advertises semaglutide today | Yes |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
★ 4.8
Google rating · 136 reviews
1
reviews in the past year (avg ★ 5.0)
1
reviews mention GLP-1 medications
42
reviews mention weight loss
Counts computed by RetaMaps from public Google reviews; most recent review 2025-12-11. Read the reviews themselves on the practice's Google listing.
Clinicians
- Dr. Angela Tran, D.O.
Nearby providers in Denver
Lea Gattoni, DMSC, PA-C - Denver: Weight Loss | Cosmetic Injector
250 Steele Street · Denver, CO 80206
5.0(29 Google reviews)
Accepts insuranceSemaglutide todayTirzepatide today18 reviews mention GLP-1
Listing updated Oct 2, 2026
Accepts insuranceSemaglutide today5 reviews mention GLP-1
Listing updated Oct 2, 2026
Cash paySemaglutide todayTirzepatide today
Listing updated Oct 2, 2026
Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs